KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Tax Assets Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deffered Revenue Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2016 - 2017)

Historic Current Deferred Revenue for Biomarin Pharmaceutical (BMRN) over the last 5 years, with Q3 2017 value amounting to $17.4 million.

Biomarin Pharmaceutical's Current Deferred Revenue changed N/A to $17.4 million in Q3 2017 from the same period last year, while for Sep 2017 it was $17.4 million, marking a year-over-year change of. This contributed to the annual value of $985000.0 for FY2016, which is N/A changed from last year.
Latest data reveals that Biomarin Pharmaceutical reported Current Deferred Revenue of $17.4 million as of Q3 2017.
Over the past 5 years, Biomarin Pharmaceutical's Current Deferred Revenue peaked at $17.4 million during Q3 2017, and registered a low of $985000.0 during Q4 2016.